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ABSTRACT
Background: Brain metastases are a significant cause of mortality and morbidity 
for patients with melanoma. We hypothesize that the development of brain metastases 
may be explained by molecular heterogeneity between primary cutaneous melanoma 
(PCM) or extracranial (ECM) and brain (MBM) melanoma metastases.
Materials and Methods: We compared next-generation sequencing, tumor 
mutational burden (TMB), and immunohistochemical staining for PD-L1 expression, 
among 132 MBM, 745 PCM, and 1190 ECM.
Results: The most common genetic alterations among MBM included: BRAF 
(52.4%), NRAS (26.6%), CDKN2A (23.3%), NF1 (18.9%), TP53 (18%), ARID2 
(13.8%), SETD2 (11.9%), and PBRM1 (7.5%).  Four genes were found with higher 
frequency among MBM compared to PCM or ECM: BRAF (52.4% v 40.4% v 40.9%), 
SETD2 (11.9% v 1.9% v 3.9%), PBRM1 (7.5% v 1.6% v 2.6%), and DICER1 (4.4% v 
0.6% v 0.4%).  MBM showed higher TMB (p = .04) and higher PD-L1 expression (p = 
.002), compared to PCM.  PD-L1 expression was slightly higher among MBM compared 
to ECM (p = .042), but there was no difference between TMB (p = .21).
Conclusions: Our findings suggest a unique molecular profile for MBM, including 
higher rates of BRAF mutations, higher TMB and higher PD-L1 expression, and also 
implicate chromatin remodeling in the pathogenesis of MBM.
INTRODUCTION
The incidence of melanoma continues to rise, with 
nearly 100,000 new cases occurring each year in the 
United States alone [1]. Among patients with advanced 
melanoma, approximately 50% develop brain metastases, 
resulting in significant morbidity and mortality [2–5]. 
Localized therapies, including surgery and radiation, have 
historically resulted in overall survival of 4-6 months for 
patients with melanoma brain metastases (MBM) [3, 5–7].
Recent clinical trials demonstrate the efficacy of 
systemic therapy in the treatment of MBM. Two studies, 
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the Anti-PD1 Brain Collaboration (ABC) and CheckMate 
204, treated patients using the combination of two 
checkpoint inhibitors (CPI), anti-CTLA-4 and anti-PD-1; 
this resulted in higher response rates compared to either 
CPI alone, and with intracranial efficacy similar to that 
seen in extracranial metastases [8, 9]. Unfortunately, there 
is no standardized biomarker to identify which MBM 
patients will best respond to CPI. While the ABC study 
demonstrated improved outcomes for patients with PD-
L1 expression greater than 1%, CheckMate 204 found no 
difference between patients with PD-L1 expression greater 
than or less than 5%.
In addition to being highly immunogenic, another 
defining characteristic of melanoma is constitutive 
activation of the MAPK pathway, via BRAF V600 
mutations. COMBI-MB study was the first clinical trial 
to demonstrate the efficacy of targeted BRAF+MEK 
inhibition for patients with BRAF mutated MBM; again, 
intra-cranial response rates were similar to that seen when 
treating extracranial metastases (ECM) [10]. However, 
responses to BRAF+MEK inhibition were less durable 
(median progression free survival 5.6 months) than 
responses in ECM, and mechanisms of resistance were 
not identified in this study.
To date, primary melanomas (PCM) and ECM 
have been extensively studied; in contrast, the biology 
of MBM remains poorly understood, largely due to 
lack of available tissue. Increasing evidence supports 
the notion that distinct tumor clones evolve throughout 
tumor progression, e.g., when comparing primary against 
metastatic tumors [11–14]. Such tumor heterogeneity may 
drive both development of metastatic disease, as well as 
resistance to cancer therapy. Brastianos and colleagues 
performed whole-exome sequencing among 86 matched 
primary tumors and brain metastases (including melanoma 
and other tumor types), and in doing so, identified unique 
genetic alterations between the matched pairs in more than 
50% of cases [11]. In MBM specifically, upregulation of 
the PI3K-AKT pathway has been consistently identified, 
suggesting its role in the pathogenesis of these tumors 
[15–17]. Furthermore, extensive research has defined 
the unique features of the brain as an anatomic site for 
metastatic seeding, encompassing: i) the blood brain barrier 
[18–20], ii) the diversity of neuronal cell types involved 
(e.g. astrocytes, microglia) [21–24], and other factors 
modulating iii) tumor cell transmigration and adhesion 
[18, 19, 25], iv) extracellular matrix degradation [23, 
26–30], and v) angiogenesis [27, 29, 31–33]. Improved 
understanding of the complex pathogenesis of MBM is 
needed to help improve clinical therapeutic approaches.
To address these gaps, we performed a cross-
sectional analysis of melanoma samples with 
comprehensive molecular profiling available via the 
Caris Life Sciences database, to examine for differences 
between MBM, when compared to PCM and other ECM.
RESULTS
Patient demographics
A total of 2,067 cutaneous melanoma samples were 
included in this analysis: 132 MBM, 745 PCM and 1190 
ECM (Figure 1). Among the 132 MBM samples, 48.5% 
originated from the supratentorial region of the brain, 
while 4.6% derived from infratentorial regions, 11.4% 
from brain stem, and 35.6% of samples did not have 
information specific to location.
Mutational profiling via next-generation 
sequencing
The most common mutations occurring among PCM 
and ECM samples, respectively, were BRAF (40.4%, 
40.9%), NRAS (27.3%, 24.2%), TP53 (18.2%, 23.0%), 
NF1 (17.9%, 26.3%) and CDKN2A (17.6%, 19.6%), 
consistent with prior studies (Figure 2A). Among MBM 
samples as well, the most frequently altered genes were: 
BRAF (52.4%), NRAS (26.6%), CDKN2A (23.3%), NF1 
(18.9%), and TP53 (18.0%). Following these top 5 genes, 
the most common altered genes, occurring in at least 5% 
or more of all MBM samples, were the following: ARID2 
(13.8%), SETD2 (11.9%), PBRM1 (7.5%), KMT2A 
(6.6%), ATRX (5.9%), IDH1 (5.6%), CTNNB1 (5.6%), 
and ARID1A (5.3%).
However, when analyzing MBM against the PCM 
cohort, the following genes were more frequently altered 
among MBM: SETD2 (11.9% v 1.9%, p = .0008), BRAF 
(52.4% v 40.4%, p = .017), PBRM1 (7.5% v 1.6%, p = 
.018), KRAS (4.0% v 1.0%, p = .026), CCND1 (2.9% 
v 0%, p = .031), and DICER1 (4.4% v 0.6%, p = 0.04) 
(Figure 2B). When analyzing MBM against ECM, higher 
rates of mutations were observed among: SETD2 (11.9% v 
3.9%, p = .009), DICER1 (4.4% v 0.4%, p = .011), AKT1 
(1.6% v 0%, p = .011), BRAF (52.4% v 40.9%, p = .019), 
and PBRM1 (7.5% v 2.6%, p = .049).
Tumor mutational burden and PD-L1
The median TMB for MBM was 17 mutations/Mb, 
while median TMB for PCM was 14 mutations/Mb, and 
median TMB for ECM was 14 mutations/Mb (Figure 3A). 
By Mann Whitney testing analysis, TMB was higher for 
MBM compared to PCM (p = .04), but there was no 
statistical difference when comparing MBM to ECM 
(p = .21).
IHC analysis revealed higher PD-L1 expression 
among MBM, compared to PCM, using a 1% cutoff 
(54.4% v 35.6%, p = .002) (Figure 3B). There was also a 
potential difference in PD-L1 expression when comparing 
MBM against ECM (54.4% v 41.8%, p = .042), and 
comparing ECM against PCM (41.8% v 35.6%, p = .048).
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Signaling pathway analysis by anatomic site and 
molecular subgroup
Pathway analysis of melanoma samples by anatomic 
site revealed higher rates of mutations affecting the MAPK 
pathway among MBM, compared to PCM (87.9% v 
77.8%, p = .015) and compared to ECM (87.9% v 77.5%, 
p = .011). The SWI/SNF pathway was also enriched with 
more alterations when comparing MBM to PCM (22.1% 
v 11.6%, p = .036), but not so when comparing MBM to 
ECM (22.1% v 17.8%, p = .49). (Supplementary Table 1).
Given the high frequency of alterations among the 
methylation, histone modification and SWI/SNF pathways 
collectively, we performed an overall grouped analysis 
for all pathways that impact chromatin modification. This 
grouped chromatin pathway analysis showed enrichment 
for more genetic alterations among MBM compared to 
PCM (23.4% v 12.3%, p = .002); however, there was only 
a trend towards significance when comparing MBM to 
ECM (23.4% v 16.2%, p = .06).
We then analyzed the 7 specific pathways among 
MBM samples stratified by TCGA molecular subgroups. 
Amongst BRAF mutated MBM, there was a higher 
frequency of alterations among the PIK3-AKT pathway, 
compared to BRAF wild type (20.0% v 5.1%, p = .027). 
Amongst the NF1 mutated subgroup, we noted higher rates 
of alterations among the SWI/SNF pathway, compared to 
NF1 wild type (60.0% v 11.6%, p = .003). No significant 
pathway differences were noted for the NRAS or triple 
wild type subgroups.
Mutational analysis of matched melanoma 
specimens
Matched melanoma specimens were available for 8 
patients with MBM within our cohort (Figure 4). Among 
these, 1 patient had a corresponding primary cutaneous 
melanoma tumor, while 3 had matched lymph node 
metastases, and 2 had matched lung metastases. There 
were 3 patients with multiple matched MBM. Among 
patients with matched samples, at least 5 demonstrated 
unique genetic alterations between anatomic sites. The 
first patient was found to have BRAF, FLT3, NPM1 
and TP53 mutations within a lung metastasis, while the 
matched brain tumor had these same mutations, as well as 
12 other mutations. A second patient harbored an NRAS 
Figure 1: Consort diagram of melanoma specimens included in the study.
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mutation in a lymph node metastasis, while the matching 
brain metastasis was NRAS wild type. The third patient 
had an NRAS mutation detected in both lymph node and 
brain metastases; however, the lymph node was wild type 
PTEN while the matched brain metastasis was PTEN 
mutated. The fourth patient had a BRAF mutation found in 
2 separate MBM, as well as the same mutations affecting 
another 22 genes; however, a single gene, ASXL1, was 
mutated in 1 brain metastasis, but wild type in the other 
brain metastasis. In a fifth patient with 3 different MBM, 
NRAS and TP53 mutations were found in all 3 tumors, 
while 2 tumors harbored mutations in 5 other genes 
(ERBB2, ERBB4, KDR, PDGFRA, PTPN11), all of 
which were wild type in the 1st tumor; in addition, 6 other 
genes were also found to have distinct mutations between 
these other 2 tumors. No differences were noted for the 
remaining patients.
DISCUSSION
Brain metastases lead to significant mortality and 
morbidity for patients with advanced melanoma, and 
improved understanding of the biology of MBM remains a 
major unmet need. Prior investigations of MBM have been 
restricted by low sample size numbers or limited by the 
scope of analyses performed. Our purpose was to leverage 
Figure 2: Comparison of gene alterations between primary cutaneous melanoma (PCM), melanoma brain metastases 
(MBM), and extracranial metastases (ECM). (A) Genes are listed in descending order of the 30 most frequent alterations identified 
in MBM. (B) Heatmap visualization of genomic alterations found across anatomic sites. Copy number variants denoted by asterisk (*).
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a large multi-center, clinical repository of melanoma 
tumors, for which multi-platform molecular testing, 
including PD-L1, TMB, and NGS were simultaneously 
available. We must note several important limitations to 
this work. First, the Caris Life Sciences tissue repository 
consists of tumor samples for which molecular profiling 
was conducted to aid in clinical decision making; as such 
there may be over-representation of tumors for which no 
standard treatments are available. Second, our analysis 
does not include clinical outcomes data to correlate with 
the molecular findings reported. Third, our NGS analysis 
was limited to a pre-specified panel of cancer-related 
genes, and reports findings at the genomic level alone; 
we were unable to corroborate our findings at the RNA or 
protein level. Nevertheless, our work presents one of the 
largest analyses of MBM to date, and should be considered 
in this context.
Prior studies have demonstrated upregulation of the 
MAPK pathway among MBM. While our analysis found 
a higher rate of BRAF mutations among MBM relative to 
PCM and ECM, we did not find a significant difference in 
the frequency of NRAS mutations; this contrasts with the 
Figure 3: Comparison of tumor mutational burden and PD-L1 expression between primary cutaneous melanoma 
(PCM), melanoma brain metastases (MBM) and extracranial metastases (ECM). (A) Box plot of tumor mutational burden 
(TMB) across distinct anatomic sites. Median TMB is listed above the bar. (B) Frequency of Tumor Samples with PD-L1 Expression 
Greater than 1%, Across Anatomic Sites.
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findings of Colombino et al., who found that the frequency 
of both BRAF and NRAS mutations was highest among 
MBM, compared to PCM or other ECM [34]. Again, we 
note the selection bias inherent to this database, which may 
have skewed the distribution of driver mutations among 
the samples presented. Nevertheless, our results showed 
alterations among genes grouped to the MAPK pathway, 
overall, in nearly 80% of MBM samples. In addition, 
when stratified by molecular subgroups, we identified 
recurrent alterations of the PI3K/AKT pathway among 
the BRAF subgroup. This is consistent with prior studies 
that describe activation of the PI3K/AKT pathway in the 
pathogenesis of MBM, and also implicate this pathway 
as a possible resistance mechanism to BRAF inhibition 
[15–17]. At least one study, by Bucheit et al., found that 
PTEN loss within BRAF V600 mutated melanomas was 
associated with significantly shorter time to development 
of MBM [15]. In the COMBI-MB study, responses to 
BRAF+MEK inhibition were less durable among MBM 
compared to ECM (median duration of response 6.5 v 
10.2 months). Patients from COMBI-MB also had shorter 
progression free survival (median 5.6 months), than 
other BRAF+MEK studies that excluded MBM (median 
9.3–14.9 months). Our findings suggest that the limited 
efficacy of BRAF+MEK inhibition in MBM may, at least 
in part, be due to molecular differences (i.e. PI3K/AKT 
activation) that exist between these anatomic sites.
Unlike lung cancer and other tumor types, the 
utility of PD-L1 as a predictive biomarker in patients 
with melanoma (and MBM) remains unclear. While high 
PD-L1 expression is felt to indicate a highly inflamed 
tumor that is more likely to respond to CPI, lack of PD-
L1 expression does not preclude a response to therapy. 
In our study, we found higher PD-L1 expression among 
MBM compared to PCM when using a cutoff of 1%; we 
also noticed that PD-L1 expression may be higher for 
MBM compared to ECM, as well as for ECM compared 
to PCM. This contrasts with a study by Kluger et al., 
who reported a trend towards lower PD-L1 expression 
among MBM compared to other ECM, although this did 
not meet statistical significance [35]. In a separate study, 
Fischer et al. found no difference in PD-L1 expression 
between MBM and ECM, although the authors did 
report up to 40% discordance between a small subset of 
matched samples [36]. It should be noted that both of these 
studies employed a different PD-L1 antibody and scoring 
system from ours. Furthermore, the study by Kluger and 
colleagues separated ECM by anatomic sites (skin, soft 
tissue, lymph node, visceral, etc). Another difference is 
that both of the aforementioned studies noted that lower 
PD-L1 expression was associated with decreased tumor 
infiltrating lymphocytes (TILs) among MBM. TILs may 
be present independently of PD-L1 expression, and thus 
are also being explored as a potential biomarker for 
Figure 4: Comparison of gene alterations between matched melanoma samples. Melanoma brain metastases (MBM) denoted 
in red, while extracranial metastases (ECM) denoted in green. Blue arrows indicate time between development of each metastasis.
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checkpoint blockade. Unfortunately, our platform did not 
allow us to comment on the presence of TILs, which may 
also explain differing response rates to CPI between MBM 
and ECM.
In addition to PD-L1, we explored TMB among 
MBM as another potential biomarker for response to 
treatment with CPI. Interestingly, we noted higher TMB 
among MBM compared to PCM, although TMB was not 
significantly higher for MBM when compared to ECM. To 
our knowledge, this is the first study to specifically describe 
TMB among MBM. While prior investigations show that 
higher TMB may be predictive of response to CPI in 
melanoma and other tumors, these studies differ in regards 
to the platform and thresholds used for assessing TMB, and 
also do not distinguish TMB across anatomic sites [37–45]. 
It should be noted that in our cohort, we did find high TMB 
levels for the upper limit range across all the compared 
anatomic subgroups. We did not appreciate a difference in 
TMB among the small subset of matched samples within 
our cohort; this is consistent with findings reported by 
Fischer et al., who performed whole-exome sequencing to 
measure overall rates of nonsynonymous mutations among 
matched samples, but found no difference between matched 
MBM and ECM [36]. Of note, the authors did not find a 
correlation between mutation rate and the presence of TILs 
within MBM [36], perhaps suggesting that TMB alone may 
not be predictive of immune response for brain metastases. 
Another finding, also concordant with prior work, was that 
patients within the NF1 subgroup had the highest TMB, 
while patients with BRAF and NRAS mutations had lower 
TMB [39, 46–48].
Our analysis demonstrated a number of genetic 
alterations that have a role in epigenetic modulation, which 
had not previously been described in the context of MBM. 
We noted higher rates of alterations in SETD2, which is 
involved in histone modification, and PBRM1, which 
encodes the BAF 180 subunit of the PBAF SWI/SNF 
chromatin remodeling complex [49, 50]. Furthermore, we 
detected recurrent alterations among the SWI/SNF pathway, 
as well as the overall grouping of all 3 chromatin modulating 
pathways (histone modification, methylation, SWI/SNF) in 
MBM. In an NGS study using a panel of 275 cancer genes 
to study 38 melanoma samples (13 PCM, 25 metastatic 
samples), Lee and colleagues found that 22.3% of all 
mutations occurred in genes affecting epigenetic regulating 
pathways, while at least 1 mutation affecting epigenetic 
regulation was present in 92% of samples [51]. Of interest, 
we detected recurrent alterations among the SWI/SNF 
pathway for the NF1 molecular subgroup; this coincides with 
prior studies showing that NF1 loss may occur concurrently 
with ARID1A mutations [46, 52]. Again, we emphasize 
that these genetic alterations should be followed by 
transcriptomic and proteomic analyses, to understand their 
functional role in MBM, and examine whether chromatin 
modifying therapies (HDAC, DNMT, and EZH2 inhibitors) 
may have any potential therapeutic application.
Regrettably, we do not have clinical outcomes to 
correlate with the findings of our investigations. Thus, we 
are unable to delineate whether these MBM developed 
de novo, or as relapsed/refractory MBM following 
therapeutic intervention, nor can we comment on other 
clinical factors which may impact outcomes in metastatic 
melanoma. Another limitation of our study is the relative 
lack of matched samples. Although we did have a large 
cohort of MBM specimens, only a small minority were 
available as matched samples from the same patient, and 
thus we cannot comment on the possibility of intra-patient 
heterogeneity. Future studies should explore not only the 
molecular heterogeneity of MBM, but also other ECM, 
as there are likely further differences reflected between 
various anatomic visceral sites (e.g. liver compared to 
lung), as well as nodal and cutaneous metastases.
In conclusion, our analysis of a large cohort of 
MBM using multiplex testing demonstrated that two 
salient features of melanoma, including: a) upregulation 
of the MAPK pathway, and b) its tumor immunogenicity, 
appear consistent among MBM, but may be modulated 
by other molecular factors not found among PCM and 
ECM. We also describe the presence of multiple genetic 
alterations associated with chromatin remodeling among 
MBM, which may suggest a novel pathway to target. 
Overall our findings indicate that molecular heterogeneity 
exists between tumors/metastases at different anatomic 
sites. Further investigation is needed to validate these 
findings and elucidate their clinical applicability.
MATERIALS AND METHODS
A total of 2,553 melanoma specimens submitted 
during routine clinical care were evaluated by 
comprehensive profiling at Caris Life Sciences (Phoenix, 
AZ) between January 2015 and October 2018. All 
specimens were grouped by primary tumor site and 
specimen site, as provided in tissue requisition requests. 
Tumor histology and diagnoses were confirmed centrally 
by board-certified pathologists based off formalin-fixed, 
paraffin-embedded (FFPE) sections. Acral, mucosal, 
conjunctival and uveal melanoma subtypes were 
excluded, as were melanoma of unknown primary and 
any melanomas without clear documentation of cutaneous 
origin. Cutaneous melanoma samples were then divided 
into 3 groups: PCM, ECM, and MBM. ECM included all 
non-CNS metastases, including visceral, skin/cutaneous, 
and nodal metastases. PCM were distinguished from skin/
cutaneous metastases based on pathology reports and 
clinical documentation by the treating physician.
Next-generation sequencing
Next-generation sequencing (NGS) was performed 
on genomic DNA isolated from FFPE tumor samples 
using the NextSeq (592-genes)/MiSeq platform (45-
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gene) to evaluate for DNA aberrations (Illumina NextSeq; 
Illumina, San Diego, CA). All variants were detected with 
greater than 99% confidence based on allele frequency 
and amplicon coverage, with an average sequencing depth 
of coverage greater than 500 and an analytic sensitivity 
of 5%. Copy number variants were generated only for 
cases profiled using the 592-gene panel. All molecular 
techniques met Clinical Laboratory Improvement 
Amendments/College of American Pathology standards.
Tumor mutational burden
Tumor mutational burden (TMB) was calculated 
using methodology as previously described by 
Vanderwalde et al. and others [53, 54]. To summarize, the 
TMB was estimated from 592 genes (1.4 megabases [MB] 
sequenced per tumor) by counting all non-synonymous 
missense mutations found per tumor that had not been 
previously described as germline alterations. TMB was 
reported as a continuous variable.
Immunohistochemistry
Immunohistochemistry (IHC) was used to assess 
protein expression; all IHC was performed on FFPE 
sections of glass slides. Positive and negative controls 
were included to ensure staining efficacy and consistency 
across batches. PD-L1 testing was performed using 
the SP142 (Ventana, Tucson, AZ) anti-PD-L1 clone as 
measured on tumor cells. PD-L1 positivity was evaluated 
using a cutoff of 1+ staining intensity on ≥ 1% of tumor 
cells.
Signaling pathway analysis
We next explored for differences in genetic 
alterations grouped by signaling pathways, as compared 
between both anatomic sites (PCM, ECM, MBM), and 
TCGA molecular subtypes (BRAF, NRAS, NF1, triple 
wild type). Commonly altered tumor suppressor genes 
and oncogenes were assigned to 7 potential signaling 
pathways of interest, as defined by the Gene Ontology 
(GO) Consortium, and the Kyoto Encyclopedia of Genes 
and Genomes (KEGG). A pathway was considered altered 
if at least one of the assigned genes or oncogenes in the 
pathway contained a genetic alteration. The pathways 
were then stratified according to anatomic site, and by 
molecular subtype (among MBM only).
Statistical analysis
Standard descriptive statistics were used for this 
retrospective analysis. For dichotomous outcomes, 
Fisher’s exact test or Pearson’s Chi-square test were 
performed. For continuous outcomes, Mann-Whitney U 
tests were conducted. A false-discovery rate adjustment 
was applied to p-values using the Benjamini-Hochberg 
method. Adjusted p-values < 0.05 were considered 
statistically significant. All analyses were conducted using 
R (version 3.5.0).
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